Tobin JWD, Keane C, Gunawardana J, et al. - Since acquiring an understanding of the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) with disease progression within 24 months (POD24) continues to be a priority, and inferior outcomes have been reported for solid tumors with low levels of intratumoral immune infiltration, researchers investigated if a similar association exists between POD24 in FL. This study included a discovery cohort comprising patients having early- and advanced-stage FL (n = 132), as well as two independent validation cohorts including patients with advanced-stage FL needing systemic therapy (n = 138, rituximab plus cyclophosphamide, vincristine, prednisone; n = 45, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Irrespective of division as an immune effector, immune checkpoint, or macrophage molecule, distinct clustering was demonstrated by immune molecules, which was characterized by either high or low expression. They found that the immune infiltration^LO [ie, low programmed death-ligand 2 (PD-L2)] subset of patients with FL was enriched for POD24 events, confirmed in the validation cohorts. In this study, the promising utility of immune-infiltration evaluation by PD-L2 expression was suggested for detecting patients who are at risk for POD24.